1
|
Abou-Jaoude A, Courtes M, Badique L, Elhaj Mahmoud D, Abboud C, Mlih M, Justiniano H, Milbach M, Lambert M, Lemle A, Awan S, Terrand J, Niemeier A, Barbero A, Houard X, Boucher P, Matz RL. ShcA promotes chondrocyte hypertrophic commitment and osteoarthritis in mice through RunX2 nuclear translocation and YAP1 inactivation. Osteoarthritis Cartilage 2022; 30:1365-1375. [PMID: 35840017 DOI: 10.1016/j.joca.2022.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 06/17/2022] [Accepted: 07/05/2022] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Chondrocyte hypertrophic differentiation, a key process in endochondral ossification, is also a feature of osteoarthritis leading to cartilage destruction. Here we investigated the role of the adaptor protein Src homology and Collagen A (ShcA) in chondrocyte differentiation and osteoarthritis. METHODS Mice ablated for ShcA in osteochondroprogenitor cells were generated by crossing mice carrying the Twist2-Cre transgene with ShcAflox/flox mice. Their phenotype (n = 5 to 14 mice per group) was characterized using histology, immuno-histology and western-blot. To identify the signaling mechanisms involved, in vitro experiments were conducted on wild type and ShcA deficient chondrocytes (isolated from n = 4 to 7 littermates) and the chondroprogenitor cell line ATDC5 (n = 4 independent experiments) using western-blot, cell fractionation and confocal microscopy. RESULTS Deletion of ShcA decreases the hypertrophic zone of the growth plate (median between group difference -11.37% [95% confidence interval -17.34 to -8.654]), alters the endochondral ossification process, and leads to dwarfism (3 months old male mice nose-to-anus length -1.48 cm [-1.860 to -1.190]). ShcA promotes ERK1/2 activation, nuclear translocation of RunX2, the master transcription factor for chondrocyte hypertrophy, while maintaining the Runx2 inhibitor, YAP1, in its cytosolic inactive form. This leads to hypertrophic commitment and expression of markers of hypertrophy, such as Collagen X. In addition, loss of ShcA protects from age-related osteoarthritis development in mice (2 years old mice OARSI score -6.67 [-14.25 to -4.000]). CONCLUSION This study reveals ShcA as a new player in the control of chondrocyte hypertrophic differentiation and its deletion slows down osteoarthritis development.
Collapse
Affiliation(s)
- A Abou-Jaoude
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - M Courtes
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - L Badique
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - D Elhaj Mahmoud
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - C Abboud
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - M Mlih
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - H Justiniano
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - M Milbach
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - M Lambert
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - A Lemle
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - S Awan
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - J Terrand
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - A Niemeier
- Department of Biochemistry and Molecular Cell Biology and Department of Orthopaedics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| | - A Barbero
- Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
| | - X Houard
- Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), F-75012 Paris, France.
| | - P Boucher
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| | - R L Matz
- UMR INSERM S_1109 University of Strasbourg, 67000 Strasbourg, France.
| |
Collapse
|
5
|
Khan KD, O’Brien S, Rai KR, Brown JR, Abboud C, Hurd DD, Conkling P, Yang Z, Haltom EJ, Uprichard MJ. Phase II study of talabostat and rituximab in fludarabine/rituximab-resistant or refractory patients with CLL. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6598] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6598 Background: Talabostat (TAL) is an orally administered small molecule inhibitor of dipeptidyl peptidases such as CD26 and fibroblast activation protein (FAP) in bone marrow, lymph nodes, and stroma of solid tumors, and TAL induces cytokine and chemokines in lymph nodes and spleen. TAL enhances the activity of rituximab (RTX) in a mouse model of lymphoma. This study evaluates the efficacy of TAL + RTX in patients with advanced CLL who failed fludarabine (FLU) and/or RTX. Methods: Single-arm, open-label study of RTX 375mg/m2 weekly × 4 weeks, and TAL-300mcg BID for 6 days following each RTX infusion for a tx course of 28 days. Additional courses permitted depending on tolerability. Eligibility criteria include ECOG PS 0–2, CD20+ B-CLL, Rai Stage III/IV or Rai I/II with marked lymphadenopathy, no CNS metastases, and primary resistance or PD following FLU and/or RTX. Primary endpoint is response rate per NCI-WG criteria. Secondary endpoints include response duration, PFS, and survival. Results: 40 patients (32 men, 8 women), median age 64.0 (range 42–83) have entered the study. Most (85%) are caucasian, and 78% of patients are Rai Stage IV. Mean serum B2 microglobulin is 6.5mg/L. The median number of prior regimens is 4 (range 1 to 10); 78% of patients received prior RTX and 33% prior alemtuzumab. Partial response (PR) has been reported in 8/36 evaluable patients (22%), 6 of whom had failed RTX; 3 of these patients had also failed alemtuzumab. Response duration currently ranges from 2 to 10 months (median 5.0 months). Most toxicities are Grade 1 or 2, and include nausea, fever (28% each), and edema (25%). Fever with associated Grade 3 or 4 neutropenia is reported in 2 and 1 patient, respectively. Other Grade 3 AEs include dyspnea (n=3), fatigue (n=2), and aspergillus pneumonia and a dermal fungal infection in 1 patient each. Grade 4 AEs are thrombocytopenia, hypoglycemia, and pulmonary embolism in 1 patient each. 4 patients died due to CLL (2 due to PD) or related complications (PE or MRSA pneumonia, 1 each). Conclusions: TAL + RTX shows promising activity in CLL patients with advanced disease who failed FLU and/or RTX. AEs are similar to those seen with RTX, with the exception of edema in 25% of patients. Updated results, including median PFS and survival will be presented at the annual meeting. [Table: see text]
Collapse
Affiliation(s)
- K. D. Khan
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - S. O’Brien
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - K. R. Rai
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - J. R. Brown
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - C. Abboud
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - D. D. Hurd
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - P. Conkling
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - Z. Yang
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - E. J. Haltom
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| | - M. J. Uprichard
- Indiana Oncology Hematology Consultants, Indianapolis, IN; M. D. Anderson Cancer Center, Houston, TX; Long Island Jewish Medical Center, New Hyde Park, NY; Dana-Farber Cancer Institute, Boston, MA; James P. Wilmot Cancer Center, Rochester, NY; Wake Forest University Health Sciences, Winston Salem, NC; Virginia Oncology Associates, Norfolk, VA; Kendle International Inc, Cincinnati, OH; Point Therapeutics, Boston, MA
| |
Collapse
|